ArticleResearch square2025

Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancer.

Jung-Min Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.